Volker Herrmann is a Flagship Pioneering CEO-partner and in this capacity serves as Chief Executive Officer of one of our newest pioneering companies, Inzen Therapeutics. Volker is a member of the broader Flagship leadership team and ecosystem, participates in Flagship leadership meetings, serves on selected Flagship company Boards, and provides his experience across our ecosystem. As Chief Executive Officer of Inzen, Volker works closely with Doug Cole and Flagship leadership to plan, drive and achieve the highest possible value creation for Flagship and for Inzen.
Prior to joining Flagship, Volker was COO and President at SQZ Biotechnologies. He has more than 20 years of experience in management, commercial development, business development, marketing and strategy. During a 17-year career at Pfizer, he held leadership roles for a variety of therapeutic areas, including European Lead CNS/Pain franchise, Global Lead Pain franchise, and Head of Global Strategy, Marketing and Commercial Development for Pfizer’s Vaccine Business Unit. Subsequently, he served as the Chief Commercial Officer for Viamet Pharmaceuticals where he was responsible for preparing the organization for the launch of their first commercial product as well as streamlining the company’s pipeline. Volker also served as the COO of Selenity Therapeutics.
Volker received his M.D. from Albert-Ludwigs University Freiburg in Germany and an M.B.A. from the University of San Diego, School of Graduate Business.